The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

The new antibiotic developed by GSK attacks a different part of the bacteria than other drugs, making it more effective against resistant organisms.

Amid a surge in drug-resistant bacteria, researchers believe they have discovered a new class of antibiotics, three decades ...

For the first time in decades, the FDA approved a new oral antibiotic to treat UTIs. Katie Donnell, 28, was a "workout queen" who was "the epitome of health" until she died of a shocking heart attack ...

The Food and Drug Administration on Tuesday approved the first drug in a new class of antibiotics for treating urinary tract infections — the first time that’s happened in nearly 30 years.

On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The medication, gepotidacin, targets E. coli bacteria, which is responsible ...

They found a new molecule named lariocidin —a potential new antibiotic with the power to kill some of the world’s most ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...

However, the increasing resistance of bacteria to standard antibiotics has made treatment more difficult. Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved ...

the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing problem of antibiotic resistance. The Fund – set up as a public-private partnership by ...